Sofosbuvir: A novel oral agent for chronic hepatitis C

Annals of Gastroenterology

Volumn 27, Issue 4, 2014, Pages 331-337

  Cholongitas, Evangelos ^a   Papatheodoridisb, George V ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Direct acting antiviral agents; Hepatitis C; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; CYCLOSPORIN; DACLATASVIR; DRUG METABOLITE; EFAVIRENZ; EMTRICITABINE; GS 331007; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5B; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PLACEBO; PROTEIN INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RIFABUTIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL ACTIVITY; ARTHRALGIA; DIARRHEA; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NAUSEA; PATIENT CARE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84920698256     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(SUPPL 1):74-81.
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-2441.
3. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26:401-412.
4. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012;26:531-548.
5. Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012;18:6060-6069.
6. Papatheodoridis GV, Cholongitas E. Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. J Viral Hepat 2004;11:287-296.
7. Cholongitas E, Papatheodoridis GV. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther 2008;27:866-884.
8. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147:132-142.e4.
9. Pawlotsky JM. Hepatitis C virus: standard-of-care treatment. Adv Pharmacol 2013;67:169-215.
10. Herbst DA, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22:527-536.
11. Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs 2014;74:273-282.
12. Kirby B, Gordi T, Symonds W, Kearney B, Mathias A. Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV infected adult subjects. Hepatology 2013;58(SUPPL 4):746A.
13. Rodriguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther 2013;11:1269-1279.
14. Cornpropst MT, Denning J, Clemons D, et al. The Effect of Renal Impairment and End Stage Renal Disease on the Single-Dose Pharmacokinetics of GS-7977. J Hepatol 2012;56:S433.
15. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
16. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
17. Pol S, Sulkowski M, Hassanein T, et al. Successful retreatment with Sofosbuvir and chronic hepatitis C 337 sofosbuvir of HCV genotype-1 infected patients who failed prior therapy with peginterferon + ribavirin plus 1 or 2 additional direct- acting antiviral agents. J Hepatol 2014;60(SUPPL 1): S23.
18. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
19. Zeuzem S, Dusheiko G, Salupere R, et al. Sofosbuvir plus ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013;58(SUPPL 4):733A.
20. Lawitz E, Poordad F, Brainanrd D, et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology 2013;58(SUPPL 4):1380A.
21. Raune P, Ain D, Riad J, et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry. Hepatology 2013;58(SUPPL 4):736A.
22. Jacobson JM, Ghalib R, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 traetment-naive and prior null responder patients: the COSMOS study. Hepatology 2013;58(SUPPL 4):1379A.
23. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.
24. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
25. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
26. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
27. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
28. Curry M, Forns X, Chung R, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013;58(SUPPL 4):314A.
29. Afdhal N, Everson G, Calleja J, et al. Sofosbuvir and ribavirin for the treatment of chronic hepatitis C with cirrhosis and portal hypertension with or without decompensation: early virologic response and safety. J Hepatol 2014;60:S23.
30. Forns X, Fontana RJ, Moonka D, et al. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation. Hepatology 2013;58(SUPPL 4):732A.
31. Charlton E, Gane E, Manns MP, et al. Sofosbuvir plus ribavirin for established recurrent HCV infection after liver trans-plantation: preliminary results of a prospective, multicenter study. Hepatology 2013;58(SUPPL 4):1378A.
32. Marino Z, van BF, Forns X, Berg T. New concepts of sofosbuvir- based treatment regimens in patients with hepatitis C. Gut 2014;63:207-215.
33. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html